Full Press Release Details
For More Information:
Chief Financial Officer
Curis, Inc. Announces Appointment of Stephen K. Carter, M.D.
to its Board of Directors
CAMBRIDGE, MA, December 19, 2007 Curis, Inc. (NASDAQ: CRIS), a drug
development company focused on seeking to develop proprietary targeted medicines primarily for cancer treatment, today announced the appointment of Stephen K. Carter, M.D. to its Board of Directors. Dr. Carter brings extensive scientific,
medical and clinical development expertise in oncology to Curis, having held executive-level clinical development positions with Bristol Myers-Squibb Pharmaceuticals and Boehringer Ingelheim Pharmaceuticals.
We are delighted to have Dr. Carter join our board, said Curis President and CEO Daniel R. Passeri, MSc., J.D. We expect that
Dr. Carter s addition will bolster our board s capacity to guide Curis in its efforts to become a leading small molecule cancer drug development company. We have made important progress this year in our cancer programs, including
advancing both our preclinical targeted cancer drug development programs and our systemically administered small molecule Hedgehog antagonist, which Genentech recently determined to advance into Phase II clinical testing in one or more solid tumor
indications in 2008. We look forward to Dr. Carter s contributions as we move forward with these programs.
Dr. Carter held a variety of senior executive research and development positions with Bristol-Myers Squibb Pharmaceuticals, an international leader in the development of innovative anticancer therapies, including serving for five years as
senior vice president of Worldwide Clinical Research and Development for its Pharmaceutical Research Institute. During his 13 year tenure at Bristol-Myers Squibb, Dr. Carter played a leading role in gaining regulatory approval of a number of
widely used cancer drugs. Following his tenure at Bristol-Myers Squibb Pharmaceuticals, from 1995 to 1996, Dr. Carter served as senior vice president of Research and Development for Boehringer Ingelheim Pharmaceuticals and, from 1998 to 2000 as
senior vice president, Clinical and Regulatory Affairs of SUGEN, Inc. (subsequently acquired by Pharmacia & Upjohn, Inc.).
Prior to his pharmaceutical industry career, Dr. Carter established and directed the Northern California Cancer
Program and also served in a number of positions during a nine-year tenure with the National Cancer Institute at the National Institutes of Health. He has also been a member of the faculties of the medical schools of Stanford University, the
University of California at San Francisco, and New York University.
I am enthusiastic about my appointment to Curis board, said
Dr. Carter. In addition to its Hedgehog antagonist programs under collaboration with Genentech, Curis has generated an impressive portfolio of preclinical small molecule targeted cancer programs. I look forward to working with the other
members of Curis board to oversee the advancement of Curis programs.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies in seeking to create new medicines, primarily for
cancer. In expanding its drug development efforts in the field of cancer through its Targeted Cancer Drug Development Platform, the Company is building upon its experiences in targeting signaling pathways in the areas of cancer, neurological disease
and cardiovascular disease. For more information, visit www.curis.com.
Cautionary Statement: This press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected contributions of Dr. Carter to our board. Forward-looking statements used in this press release may contain the words
believes , expects , anticipates , plans , seeks , estimates , will , may or similar expressions. These forward-looking statements are not guarantees of future
performance and involve risks, uncertainties, assumptions and other factors that may cause our actual results to be materially different from those indicated by such forward-looking statements including, among other things:
In addition, any forward-looking statements represent our views only as of today and
should not be relied upon as representing its views as of any subsequent date. We disclaim any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information,
future events or otherwise.